ISSN: 0344-5704

Journal Home

Journal Guideline

Cancer Chemotherapy and Pharmacology Q1 Unclaimed

Springer Verlag Germany

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer Chemotherapy and Pharmacology is a journal indexed in SJR in Pharmacology and Oncology with an H index of 122. It has a price of 3060 €. It has an SJR impact factor of 0,869 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,869.

Cancer Chemotherapy and Pharmacology focuses its scope in these topics and keywords: cell, human, patients, kinase, breast, highdose, etoposide, combination, correlation, sensitivity, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Toxicology (Q1) Cancer Research (Q2) Oncology (Q2) Pharmacology (Q2) Pharmacology (medical) (Q2) Pharmacology (medical) (Q2)

Price

3060 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,869

SJR Impact factor

122

H Index

109

Total Docs (Last Year)

496

Total Docs (3 years)

3935

Total Refs

1395

Total Cites (3 years)

488

Citable Docs (3 years)

2.73

Cites/Doc (2 years)

36.1

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Pharmacological Reviews Q1
Drug Resistance Updates Q1
Annual Review of Pharmacology and Toxicology Q1
Molecular Therapy Q1
Journal for ImmunoTherapy of Cancer Q1

Compare this journals

Aims and Scope

Best articles by citations

Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer

Peptides designed from molecular modeling studies of the ras -p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth

Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice

Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil

Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells

Structural development of synthetic retinoids and thalidomide-related molecules

Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay

Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents

SHOW MORE ARTICLES

Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

Granisetron: is there a dose?response effect on nausea and vomiting?

BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhR

Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates

An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study

Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer

Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers